Adjuvant therapy for noncolorectal cancers

Current Opinion in Oncology

Volumn 13, Issue 4, 2001, Pages 287-290

  Ilson, David H ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADJUVANT THERAPY; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; ESOPHAGUS CANCER; HIGH RISK POPULATION; HUMAN; MORTALITY; PANCREAS CANCER; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; PANCREATIC NEOPLASMS; RECTAL NEOPLASMS; STOMACH NEOPLASMS;

EID: 0034955089     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200107000-00012     Document Type: Review

References (18)

1. Cancer statistics, 2000
2. Outcome of patients receiving radiation for cancer of the esophagus: Results of the 1992-1994 Patterns Care Study
3. Phase II evaluation of preoperative chemoradiation and preoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus
4. Combined chemotherapy and radiation compared with radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus
5. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer
6. Medical Research Council randomized trial of surgery with or without preoperative chemotherapy in resectable cancer of the esophagus
7. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): Final report
8. Preliminary results of Intergroup INT 0123 randomized trial of combined modality therapy (CMT) for esophageal cancer: Standard vs. high dose radiation therapy
9. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
10. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma
11. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomized trials
12. Resected gastric adenocarcinoma: Randomized trial of adjuvant chemotherapy with 5 fu-cisplatin (FUP). Final results of the FFCD 8801 trial
13. Improved adjuvant therapy outcome in resected gastric cancer patients according to node involvement. 5-Year results of randomized study by the Italian Trials in Medical Oncology (ITMO) group
14. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and g.e. junction. Results of Intergroup study int-0116 (SWOG 9008)
15. Postoperative adjuvant chemoradiation therapy for patients with resected gastric cancer: Intergroup 116
16. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection
17. Adjuvant radiotherapy and 5-flourouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group
18. ESPAC-1 Interim results: A European, randomized study to assess the roles of adjuvant chemotherapy (5-fu + folinic acid) and adjuvant chemoradiation (40gy + 5-fu) in resectable pancreatic cancer